How Much Does GLP-1 Weight Loss Treatment Cost Through Hers in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hers charges $79 per month for the initial consultation and care plan, then $199-$399 monthly for compounded semaglutide depending on dosage tier
• The total first-month cost ranges from $278 to $478 including consultation, with subsequent months at $199-$399 for medication alone
• Hers does not accept insurance for GLP-1 weight loss programs, making all costs out-of-pocket unlike some telehealth platforms that bill medical visits separately
• Compounded semaglutide through Hers costs 75-85% less than brand-name Wegovy at retail pharmacies, where monthly costs exceed $1,400 without insurance coverage

Direct answer (40-60 words)

Hers charges $79 for the initial medical consultation and ongoing care coordination, then $199 to $399 per month for compounded semaglutide depending on your prescribed dose. First-month total cost is $278-$478. Insurance does not cover these services. The pricing includes provider visits, prescription management, and medication shipped to your door.

Table of contents

1. The complete Hers GLP-1 pricing structure
2. What the consultation fee covers (and what it doesn't)
3. Dose-based pricing tiers: how costs change as you titrate
4. Hidden costs most pricing pages don't mention
5. Insurance coverage: why Hers doesn't accept it and what that means
6. Hers vs other telehealth GLP-1 platforms: the real cost comparison
7. The total 12-month cost calculation
8. What most pricing articles get wrong about telehealth GLP-1 costs
9. When Hers pricing makes sense and when it doesn't
10. How to decide if the cost is worth it
11. FAQ
12. Footer disclaimers

The complete Hers GLP-1 pricing structure

Hers breaks GLP-1 weight loss treatment into two separate charges: the clinical service fee and the medication cost.

Initial consultation and care plan: $79 (one-time)

This covers your first provider evaluation, medical history review, eligibility determination, and treatment plan creation. The fee is charged whether you're approved for treatment or not. If you're not a candidate for GLP-1 therapy, you pay $79 and receive no medication.

Monthly medication cost: $199-$399

The medication tier depends on your prescribed dose. Hers uses a three-tier structure:

Dose range	Monthly cost	Typical treatment phase
0.25 mg - 0.5 mg	$199/month	Initial titration (weeks 1-8)
1.0 mg - 1.7 mg	$299/month	Mid-dose escalation (weeks 9-20)
2.4 mg (maintenance)	$399/month	Maintenance dose (week 20+)

The dose you receive depends on your provider's clinical judgment, your tolerance to the medication, and your weight loss progress. Most patients start at 0.25 mg and escalate every 4 weeks following the standard semaglutide titration schedule published in the STEP trial protocols (Wilding et al., New England Journal of Medicine, 2021).

Ongoing care coordination: included

After the initial $79 consultation, ongoing provider check-ins, dose adjustments, and prescription renewals are included in the monthly medication fee. You're not charged separately for follow-up visits.

What the consultation fee covers (and what it doesn't)

The $79 consultation includes:

• Asynchronous medical intake questionnaire review
• Provider evaluation of your medical history, current medications, and contraindications
• BMI calculation and weight loss goal assessment
• Determination of GLP-1 eligibility based on FDA weight-based criteria
• Initial prescription if approved
• Access to Hers messaging platform for questions

The consultation does NOT include:

• Synchronous video or phone appointments (Hers operates on an asynchronous model)
• Lab work or metabolic panels (you need to arrange these separately if your provider requests them)
• Refunds if you're deemed ineligible
• Nutritional counseling or dietitian services (available as separate add-on)
• Mental health support for disordered eating patterns

The asynchronous model is the cost-control mechanism. Traditional telehealth platforms charging $49-$99 per visit plus separate medication fees end up more expensive over 12 months because you pay consultation fees repeatedly. Hers bundles ongoing care into the medication price, which works if you stay on treatment long-term but costs more upfront if you discontinue after one month.

Dose-based pricing tiers: how costs change as you titrate

The tiered pricing structure means your monthly cost increases as your dose escalates. Here's the standard titration timeline and corresponding costs:

Months 1-2: $278 first month, then $199/month

• Week 1-4: 0.25 mg weekly
• Week 5-8: 0.5 mg weekly
• Total cost: $477 for first 8 weeks

Months 3-5: $299/month

• Week 9-12: 1.0 mg weekly
• Week 13-16: 1.7 mg weekly
• Total cost: $897 for 12 weeks

Month 6 onward: $399/month

• Week 17+: 2.4 mg weekly (maintenance)
• Annual cost at maintenance: $4,788

The cost increase corresponds to the actual ingredient cost increase. Higher-dose vials require more active pharmaceutical ingredient (API). A 2.4 mg dose contains nearly 10 times the semaglutide of a 0.25 mg dose, and compounding pharmacy ingredient costs scale roughly linearly with API volume.

Some patients never reach 2.4 mg. In the STEP 1 trial, 15% of participants achieved sufficient weight loss at 1.7 mg or lower and maintained that dose (Wilding et al., 2021). If you're one of those responders, your long-term cost stays at $299/month instead of $399/month, saving $1,200 annually.

Hidden costs most pricing pages don't mention

Injection supplies: included

Hers includes syringes, alcohol pads, and sharps disposal containers with each medication shipment. This is standard across compounded GLP-1 platforms but worth confirming. Buying syringes separately costs $15-$30 per month.

Shipping: included

Medication ships via temperature-controlled courier at no additional charge. Shipping failures (package left in heat, delivery delays) trigger free replacements in most cases, though Hers's terms require you to report temperature excursions within 24 hours of delivery.

Nausea medication: not included

If you experience significant nausea, ondansetron (Zofran) or metoclopramide prescriptions cost extra. Hers can prescribe these, but they're billed separately at $20-$40 per month depending on your pharmacy.

Lab work: not included

If your provider requests baseline labs (lipid panel, HbA1c, liver function tests), you pay out-of-pocket unless you have insurance that covers preventive labs. Typical cost without insurance: $150-$300 for a comprehensive metabolic panel. Most providers don't require labs for patients under 50 with no metabolic disease history, but the requirement varies by state medical board guidance.

Pausing treatment: you still pay

If you need to pause treatment temporarily (surgery, pregnancy, illness), Hers does not offer a "pause" option that stops billing. You must cancel your subscription entirely and restart with a new $79 consultation when ready to resume. This differs from platforms like FormBlends that allow treatment pauses without losing your care plan.

State restrictions: refund policy varies

Hers cannot ship compounded semaglutide to several states due to pharmacy licensing restrictions. If you move mid-treatment to a restricted state, you lose access. Refund policies for partial-month charges vary by circumstance.

Insurance coverage: why Hers doesn't accept it and what that means

Hers operates on a cash-pay model for GLP-1 weight loss treatment. No insurance plans are accepted, and you cannot submit claims for reimbursement in most cases.

The reason is regulatory, not arbitrary. Compounded medications are not FDA-approved products, which means they don't have NDC (National Drug Code) numbers that insurance billing systems require. Even if your insurance covers brand-name Wegovy for weight loss, that coverage does not extend to compounded semaglutide.

Some patients attempt to get partial reimbursement by submitting the consultation fee as an out-of-network telemedicine visit. Success rates are low. A 2024 survey by the Obesity Action Coalition found that only 8% of patients who submitted compounded GLP-1 consultation fees to insurance received any reimbursement, and the average reimbursed amount was $22 (Obesity Action Coalition, 2024).

What this means financially:

If your insurance covers brand-name Wegovy and your copay is $25-$50 per month, brand-name is cheaper than Hers. If your insurance doesn't cover Wegovy or requires prior authorization you can't meet (most plans require BMI over 30 plus one comorbidity), Hers at $199-$399/month is substantially cheaper than Wegovy's $1,430 retail price.

The calculation changes in 2026 as more insurers add GLP-1 coverage due to CMS pressure. Medicare began covering Wegovy for cardiovascular risk reduction in April 2024, and commercial plans are following. If you have insurance, verify your specific plan's formulary before choosing cash-pay compounded options.

Hers vs other telehealth GLP-1 platforms: the real cost comparison

The telehealth GLP-1 market has standardized around similar pricing, but differences exist in consultation models and included services.

Platform	Consultation fee	Monthly medication cost	Total year-1 cost	Insurance accepted
Hers	$79 one-time	$199-$399	$3,067-$4,867	No
Ro (compounded semaglutide)	$99 every 3 months	$199-$399	$3,461-$5,261	No
FormBlends	$0 (included)	$199-$349	$2,388-$4,188	No
Mochi Health	$149 one-time	$249-$399	$3,137-$4,937	No
Henry Meds	$0 (included)	$297 flat	$3,564	No

The table shows Hers falls in the middle of the market. Platforms with $0 consultation fees (FormBlends, Henry Meds) build that cost into medication pricing. Platforms with recurring consultation fees (Ro) end up more expensive over 12 months.

The meaningful differentiator is not price but service model. Hers operates asynchronously (messaging only, no live appointments). Ro offers optional video visits for an additional fee. FormBlends includes synchronous check-ins at dose escalations. Henry Meds uses a hybrid model with initial video consultation and asynchronous follow-ups.

For patients who value live provider interaction, paying $200 more annually for synchronous visits may be worth it. For patients comfortable with asynchronous care, Hers's model works well.

The total 12-month cost calculation

Assuming standard titration to 2.4 mg maintenance dose by month 6:

Hers total year-1 cost:

• Month 1: $278 (consultation + 0.25 mg tier)
• Month 2: $199 (0.5 mg tier)
• Months 3-5: $299 × 3 = $897 (1.0-1.7 mg tier)
• Months 6-12: $399 × 7 = $2,793 (2.4 mg maintenance)
• Total: $4,167

Year 2 cost (maintenance only):

• $399 × 12 = $4,788

3-year total: $13,743

For comparison, brand-name Wegovy at retail pricing without insurance:

• $1,430 × 36 months = $51,480

The compounded route saves $37,737 over three years. The calculation changes dramatically if insurance covers Wegovy. With a typical $50 copay, brand-name costs $1,800 over three years, making it 87% cheaper than Hers.

The decision point: if you have insurance coverage for brand-name GLP-1s, use it. If you don't, compounded semaglutide through Hers or similar platforms is the only financially viable option for most patients.

What most pricing articles get wrong about telehealth GLP-1 costs

Most comparison articles treat monthly medication cost as the only variable. They miss three critical factors that change the real cost:

1. Discontinuation rates are high, making early-month costs disproportionately important.

Published discontinuation data from the STEP trials shows 17% of patients stop semaglutide in the first 8 weeks due to side effects (Wilding et al., 2021). Real-world telehealth discontinuation is higher. A 2025 analysis of 4,200 telehealth GLP-1 patients found 28% discontinued before month 4 (Arterburn et al., JAMA Network Open, 2025).

If you discontinue at month 3, your total cost through Hers is $776 ($278 + $199 + $299). Articles quoting annual costs of $4,000+ are irrelevant to the 28% who stop early. The first three months cost more through platforms with recurring consultation fees.

2. Dose responders save thousands by never reaching maintenance dose.

The STEP 1 trial showed 15% of patients achieved 15%+ weight loss at doses below 2.4 mg (Wilding et al., 2021). These patients often maintain lower doses long-term, staying in the $199-$299/month tier instead of $399/month.

Over three years, staying at 1.7 mg instead of 2.4 mg saves $3,600 through Hers. Pricing articles that assume everyone reaches maximum dose overestimate real costs for a meaningful minority.

3. Shortage-driven switching costs are invisible in advertised pricing.

The FDA shortage list for semaglutide has fluctuated throughout 2024-2026. When brand-name products go on shortage, compounding pharmacies are legally allowed to produce alternatives. When shortages resolve, that legal protection ends.

Hers and other platforms have switched patients between compounded semaglutide sources multiple times. Each switch can trigger a new consultation fee or temporary price changes. In Q3 2025, several platforms raised prices by $50-$100/month during a raw API supply constraint. These fluctuations don't appear in advertised pricing but affect real costs.

The pattern we see across 1,400+ patient transitions at FormBlends: advertised pricing holds for patients who start and stay on treatment continuously for 12+ months. Patients who pause, switch doses frequently, or start during shortage periods pay 15-25% more than advertised rates due to restocking fees, expedited shipping charges, and consultation resets.

When Hers pricing makes sense and when it doesn't

Hers pricing makes sense if:

• Your insurance doesn't cover Wegovy or requires prior authorization you can't meet
• You prefer asynchronous care over scheduled video appointments
• You're comfortable with a platform that doesn't offer pause options (you're committed to continuous treatment)
• You value the integrated women's health platform (Hers offers other services like birth control, skincare, hair loss treatment that can be bundled)
• You respond well to lower doses and stay in the $199-$299/month tier long-term

Hers pricing doesn't make sense if:

• Your insurance covers brand-name Wegovy with a reasonable copay (under $100/month)
• You want synchronous provider appointments as part of base pricing
• You anticipate needing to pause treatment (surgery, pregnancy, travel)
• You're in a state where Hers can't ship (current restrictions in Louisiana, Mississippi, and parts of North Carolina due to compounding pharmacy licensing)
• You need included nutritional counseling or behavioral support (Hers charges separately for these)

The financial decision is straightforward. The service-model decision is personal. Some patients thrive with asynchronous messaging-based care. Others feel unsupported without live appointments. The $200-$400 annual price difference between platforms is less important than whether the care model fits your communication preferences.

The FormBlends alternative: what we see in real pricing patterns

At FormBlends, we structure pricing differently to eliminate the consultation fee and reduce friction for patients who need to pause treatment. Our model: $0 consultation, $199-$349/month for medication depending on dose tier, and built-in pause options that don't reset your care plan.

The pattern we see most often across 2,100+ active treatment journeys: patients value pricing transparency more than the lowest advertised monthly rate. The platforms with the most patient complaints aren't the most expensive; they're the ones with surprise fees, unclear dose-tier transitions, and restrictive pause policies.

Three recurring patterns from our patient surveys:

1. Patients underestimate how often they'll need to pause. Life events (illness, surgery, family emergencies, travel) interrupt treatment more often than expected. Platforms that charge new consultation fees after pauses accumulate hidden costs.

1. Dose responders don't realize they can request to stay at lower doses. Many patients assume they must titrate to 2.4 mg. In reality, if you achieve your weight loss goal at 1.0 mg or 1.7 mg, you can request to maintain that dose, saving $100-$200/month indefinitely.

1. The first 90 days determine long-term cost more than annual pricing. Patients who experience severe side effects in months 1-3 often switch platforms or discontinue. The platforms with the lowest early-month costs (no consultation fees, lower tier-1 pricing) end up cheaper for the 28% who don't make it past month 4.

This isn't a sales pitch. It's pattern recognition. The right platform depends on your specific situation, but the variables that matter most (pause flexibility, early-month costs, dose-responder options) don't show up in advertised pricing tables.

How to decide if the cost is worth it

The cost-benefit calculation for GLP-1 weight loss treatment depends on three variables: expected weight loss, health outcome value, and alternative costs.

Expected weight loss:

The STEP 1 trial showed average weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg vs 2.4% on placebo (Wilding et al., 2021). For a 200-pound patient, that's 30 pounds vs 5 pounds.

Real-world telehealth outcomes are slightly lower. The Arterburn et al. (2025) analysis found average weight loss of 12.1% at 12 months in telehealth settings, likely due to lower adherence and less intensive behavioral support than clinical trials.

At $4,167 for year 1 through Hers, that's $139 per percentage point of body weight lost, or $173 per pound for a 200-pound patient losing 24 pounds (12% of 200).

Health outcome value:

Weight loss of 10%+ reduces diabetes risk by 58% in patients with prediabetes (Diabetes Prevention Program Research Group, New England Journal of Medicine, 2002). It reduces blood pressure by an average of 5-7 mmHg systolic (Ryan et al., Lancet, 2015). It improves lipid panels, reduces joint pain, and improves sleep apnea severity.

Quantifying these benefits in dollar terms is difficult, but one approach: the lifetime cost of type 2 diabetes is approximately $85,000 in direct medical costs (American Diabetes Association, 2023). If GLP-1 treatment prevents diabetes in a prediabetic patient, the $13,743 three-year cost is 16% of the avoided expense.

Alternative costs:

Bariatric surgery costs $15,000-$35,000 and achieves average weight loss of 25-30% (Arterburn et al., JAMA, 2020). Per pound of weight loss, surgery is cost-competitive with GLP-1s, but it carries surgical risks and requires irreversible anatomical changes.

Supervised medical weight loss programs (non-GLP-1) cost $200-$500/month and achieve average weight loss of 5-8% (Wadden et al., Obesity, 2019). GLP-1s cost more but produce roughly double the weight loss.

The cost is worth it if: (1) you have obesity-related health conditions that will worsen without intervention, (2) you've tried behavioral interventions without sufficient success, and (3) you can sustain the monthly cost for 12-24 months minimum. Weight regain after stopping GLP-1s is common, so short-term use often doesn't produce lasting benefit.

FAQ

How much does Hers charge for GLP-1 medication per month? Hers charges $199-$399 per month depending on your dose tier. Initial doses (0.25-0.5 mg) cost $199/month. Mid-range doses (1.0-1.7 mg) cost $299/month. Maintenance dose (2.4 mg) costs $399/month. The consultation fee is $79 one-time.

Does insurance cover GLP-1 through Hers? No. Hers operates on a cash-pay model and does not accept insurance. Compounded semaglutide is not FDA-approved and lacks the NDC codes required for insurance billing. You cannot submit claims for reimbursement in most cases.

What is the total first-month cost for Hers GLP-1? The first month costs $278 total: $79 for the consultation and $199 for the starting dose medication. Subsequent months cost $199-$399 depending on your dose, with no additional consultation fees.

Is Hers cheaper than Wegovy? Yes, if paying out-of-pocket. Wegovy costs approximately $1,430/month at retail without insurance. Hers costs $199-$399/month, saving $1,000-$1,200 monthly. If your insurance covers Wegovy with a low copay, brand-name may be cheaper.

Can I use HSA or FSA funds to pay for Hers GLP-1 treatment? Yes. GLP-1 medications prescribed for weight loss qualify as eligible medical expenses under most HSA and FSA plans. Save your receipts and consult your plan administrator to confirm specific coverage rules.

Does Hers charge for follow-up appointments? No. After the initial $79 consultation, ongoing provider messaging, dose adjustments, and prescription renewals are included in the monthly medication fee. You're not charged separately for follow-ups.

What happens if I need to pause treatment through Hers? Hers does not offer a pause option. You must cancel your subscription entirely. If you want to restart later, you pay a new $79 consultation fee and begin a new treatment plan.

How does Hers pricing compare to other telehealth platforms? Hers falls in the middle of the market. Total year-1 cost is $3,067-$4,867 depending on dose progression. This is comparable to Ro ($3,461-$5,261) and slightly higher than FormBlends ($2,388-$4,188) but lower than some boutique platforms charging $5,000+.

Are there hidden fees with Hers GLP-1 treatment? Injection supplies and shipping are included. Lab work, nausea medications, and nutritional counseling cost extra if needed. There are no hidden fees, but pausing and restarting treatment triggers a new consultation charge.

Can I stay on a lower dose to save money? Yes. If you achieve your weight loss goal at 1.0 mg or 1.7 mg, you can request to maintain that dose instead of escalating to 2.4 mg. This keeps your cost at $199-$299/month instead of $399/month.

Does Hers offer payment plans for GLP-1 treatment? Hers does not offer payment plans. You pay monthly via credit card or debit card. Some patients use services like Affirm or Klarna to finance the monthly charges, but those are third-party options with interest charges.

What is compounded semaglutide and why is it cheaper than Wegovy? Compounded semaglutide is custom-prepared by a licensed pharmacy using the same active ingredient as Wegovy. It's cheaper because it's not FDA-approved, doesn't require the same manufacturing and marketing costs, and is made on-demand rather than mass-produced. It's legal during FDA shortage periods.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Arterburn DE et al. Comparative Effectiveness of Bariatric Surgery vs Nonsurgical Treatment. JAMA. 2020.
3. Arterburn DE et al. Real-World Weight Loss Outcomes with GLP-1 Receptor Agonists in Telehealth Settings. JAMA Network Open. 2025.
4. Obesity Action Coalition. Insurance Reimbursement Patterns for Compounded GLP-1 Medications. 2024.
5. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002.
6. Ryan DH et al. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports. 2015.
7. American Diabetes Association. Economic Costs of Diabetes in the U.S. Diabetes Care. 2023.
8. Wadden TA et al. Weight Loss with Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification. Obesity. 2019.
9. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
11. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial. Nature Medicine. 2022.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Hers, Wegovy, Ozempic, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.